Start here if you're new
what it is
Kyntra Bio develops cancer and rare-disease drugs and sells roxadustat outside the U.S. with 225 employees.
how it gets paid
Last year Kyntra Bio made $30M in revenue. Roxadustat commercial sales was the main engine at $18M, or 60% of sales.
what just happened
Quarterly revenue hit $5M, while EPS landed at $48.90.
At a glance
C+ balance sheet — struggling to keep the lights on
10/100 earnings predictability — expect surprises
-$38.25 fy2024 eps est
$2B fy2026 rev est
n/a operating margin
xvary composite: 22/100 — weak
What they do
Kyntra Bio develops cancer and rare-disease drugs and sells roxadustat outside the U.S. with 225 employees.
Roxadustat is already approved in Europe, Japan, and other countries. That is one commercial drug versus two pipeline bets, and your money is backing a 225-person team. FG-3246 is in Phase 2, which means mid-stage human testing, not sales.
How they make money
$30M
annual revenue
Roxadustat commercial sales
$18M
37.5%
Collaboration and license revenue
$7M
37.5%
FG-3246 program support
$3M
0.0%
Other rare-disease revenue
$2M
0.0%
The products that matter
legacy commercialization
Roxadustat & Legacy
$6.4M · down from $29.6M
it's the only reported revenue stream on this page, and it fell 78% from last year. That's a shrinking source of support, not the reason to own the stock.
current revenue
lead oncology asset
FG-3246
H2 2026 interim phase 2
this is the asset the market actually cares about. With a $28M market cap and just $6.4M of annual revenue, the next meaningful value inflection is clinical, not commercial.
main catalyst
pipeline funding base
Cash runway
$109.4M · roughly 1.5 years
cash is not a product, but it is the operating reality. Guided annual operating expenses of $80M–$85M tell you management has time to reach data, not time to waste.
time bought
Key numbers
$30M
ttm revenue
That is the whole business right now. Compare it with the $2B FY2026 sales estimate and the gap gets ridiculous.
n/a
op margin
Prior margin KPI failed sanity check — verify in filings. Every dollar of sales comes with about $5.08 of operating loss. That is not scale yet.
$20M
debt
Debt is 41% of capital. For a $28M company, that is real weight.
1.9
beta
The stock moves about twice the market. Your timing matters more than usual.
Financial health
C+
strength
- balance sheet grade C+ — weak — may struggle to fund operations
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $20M (41% of capital)
C+ — balance sheet grade and long-term debt are flagged. this stock carries more risk than average.
Total return vs. market
Return history isn't available for KYNB right now.
source: institutional data · return history unavailable
What just happened
beat estimates
Quarterly revenue hit $5M, while EPS landed at $48.90.
EDGAR shows revenue up 380% vs. prior year. EPS was down 1% vs. prior year, so the line items are moving in opposite directions.
$5M
revenue
$48.90
eps
+380%
rev vs. last year
the number that mattered
The $5M top line matters because it is still tiny beside the $30M annual run rate.
source: company earnings report, 2026
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. plain english, no spam.
weekly updates
earnings alerts
plain english
no spam
What could go wrong
the #1 risk is FG-3246 failing to produce convincing Phase 2 data.
med
FG-3246 disappoints
With only $6.4M in annual revenue, there is not much operating business here to catch you if the lead asset stumbles. This is what pipeline concentration looks like in real life.
A weak readout would pressure the core reason investors own the stock and could force the market to value KYNB closer to its cash burn than its science.
med
runway shortens before the catalyst arrives
$109.4M of cash sounds healthy until you stack it against $80M–$85M in expected annual operating expenses. If spending runs hot or timing slips, financing risk shows up fast.
That would matter because dilution becomes part of the thesis, not just a background possibility.
med
the legacy business keeps shrinking
Revenue fell from $29.6M to $6.4M. The market already treats that business as runoff, but further deterioration still removes one more layer of support under the balance sheet story.
If legacy revenue fades faster than expected, more of the valuation has to sit on FG-3246 and less can sit on existing operations.
$6.4M of revenue against $80M–$85M of annual operating expense tells you the same thing three different ways: this is a binary biotech with a clock attached.
source: institutional data · regulatory filings · risk analysis
Pay attention to
calendar
H2 2026 FG-3246 interim data
This is the event the whole page bends around. If timing slips, your runway math gets tighter immediately.
metric
cash versus operating expense
Keep $109.4M of cash next to the $80M–$85M expense guide. That is the cleanest way to track how much patience the company can afford.
risk
legacy revenue runoff
A drop from $29.6M to $6.4M tells you the old business is not the safety net. If it falls further, the stock becomes even more single-asset in practice.
trend
whether the story gets simpler
Right now you own a biotech between old revenue and new science. A cleaner setup would mean either stronger data or clearer capital planning. Preferably both.
Analyst rankings
short-term outlook
mixed
analyst target data is thin here. in human-speak: there is no sturdy consensus to hide behind.
risk profile
volatile
a 1.9 beta and 5/100 price stability tell you this name trades like a catalyst vehicle, not a steady compounder.
chart momentum
stock-specific
this is the kind of chart that listens to trial timing, financing risk, and headlines more than neat technical patterns.
earnings predictability
10/100
you are not buying a company with repeatable quarterly rhythm. You are buying a company still changing what it is.
source: institutional data
Institutional activity
institutional ownership data for KYNB is being compiled.
source: institutional data
Price targets
3-5 year target range
n/a
n/a
$7
current price
n/a
target midpoint · n/a from current
Want the deeper analysis?
The full deep dive: dcf model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
see plans from $5/moThe deep dive